Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma (ZUMA-14)

NCT04002401 is registered in ClinicalTrials.gov with Kite, A Gilead Company as lead sponsor.

NCT NCT04002401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04002401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma (ZUMA-14)
Lead sponsor
Kite, A Gilead Company
Phase
Phase 2
Overall status
Completed
Start date
November 5, 2019
Completion date
January 30, 2023
Enrollment
27 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

refractory large b-cell lymphoma